Literature DB >> 17241216

Myoclonic status in nonprogressive encephalopathies: study of 29 cases.

Roberto Horacio Caraballo1, Ricardo Oscar Cersósimo, Alberto Espeche, Hugo Antonio Arroyo, Natalio Fejerman.   

Abstract

PURPOSE: Myoclonic status in nonprogressive encephalopaties (MSNE) is characterized by recurrence of long-lasting myoclonic status appearing in infants and young children with nonprogressive encephalopathy. Here, we describe the electroclinical features and evolution of MSNE.
METHODS: Between February 1, 1990 and July 31, 2005, 29 patients who met diagnostic criteria of MSNE were enrolled in the study at our department and have been followed up to the present time.
RESULTS: Three main subgroups could be identified. The first subgroup of 18 patients presented myoclonic absences and rhythmic myoclonias. These were followed by a brief silent period related to a subcontinuous delta-theta activity involving the central areas, and rhythmic delta waves with superimposed spikes mainly involving the parietooccipital regions and often activated by eye closure. It was found in all children with a genetic etiology. The second subgroup included five patients showing a pattern characterized by inhibitory phenomena associated with a dystonic component and sudden irregular rapid lightning-like jerks. The EEG showed subcontinuous multifocal slow spike-waves, predominating in frontocentral regions. These patients are affected by a cortical malformation or the etiology is unknown. The third subgroup included six children who initially suffered from myoclonic absences. The status was initially characterized by subcontinuous generalized spike-wave-type paroxysms related to rhythmic myoclonia of face and limbs. After 1-3 weeks, the EEG showed sharp theta waves with very slow pseudorhythmic continuous spikes in the central regions and vertex. The etiology was found to be perinatal anoxic injury.
CONCLUSION: MSNE should be considered as a new epileptic syndrome in the group of epileptic encephalopathy.

Entities:  

Mesh:

Year:  2007        PMID: 17241216     DOI: 10.1111/j.1528-1167.2006.00902.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  5 in total

Review 1.  Early-onset epileptic encephalopathies and the diagnostic approach to underlying causes.

Authors:  Su-Kyeong Hwang; Soonhak Kwon
Journal:  Korean J Pediatr       Date:  2015-11-22

Review 2.  Epileptic encephalopathies: new genes and new pathways.

Authors:  Sahar Esmaeeli Nieh; Elliott H Sherr
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

3.  Migrating Focal Seizures and Myoclonic Status in ARV1-Related Encephalopathy.

Authors:  Francesca Darra; Tommaso Lo Barco; Roberta Opri; Elena Parrini; Claudia Bianchini; Elena Fiorini; Alessandro Simonati; Bernardo Dalla Bernardina; Gaetano Cantalupo; Renzo Guerrini
Journal:  Neurol Genet       Date:  2021-05-14

4.  Genetic and epileptic features in Rett syndrome.

Authors:  Hyo Jeong Kim; Shin Hye Kim; Heung Dong Kim; Joon Soo Lee; Young-Mock Lee; Kyo Yeon Koo; Jin Sung Lee; Hoon-Chul Kang
Journal:  Yonsei Med J       Date:  2012-05       Impact factor: 2.759

Review 5.  A multidisciplinary approach and consensus statement to establish standards of care for Angelman syndrome.

Authors:  Jessica Duis; Mark Nespeca; Jane Summers; Lynne Bird; Karen G C B Bindels-de Heus; M J Valstar; Marie-Claire Y de Wit; C Navis; Maartje Ten Hooven-Radstaake; Bianca M van Iperen-Kolk; Susan Ernst; Melina Dendrinos; Terry Katz; Gloria Diaz-Medina; Akshat Katyayan; Srishti Nangia; Ronald Thibert; Daniel Glaze; Christopher Keary; Karine Pelc; Nicole Simon; Anjali Sadhwani; Helen Heussler; Anne Wheeler; Caroline Woeber; Margaret DeRamus; Amy Thomas; Emily Kertcher; Lauren DeValk; Kristen Kalemeris; Kara Arps; Carol Baym; Nicole Harris; John P Gorham; Brenda L Bohnsack; Reid C Chambers; Sarah Harris; Henry G Chambers; Katherine Okoniewski; Elizabeth R Jalazo; Allyson Berent; Carlos A Bacino; Charles Williams; Anne Anderson
Journal:  Mol Genet Genomic Med       Date:  2022-02-11       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.